{"id":"W3214653934","doi":"10.1158/2159-8290.cd-21-1141","title":"Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Takeda Oncology; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Natera; Chugai Pharmaceutical; Seagen; Array BioPharma; OncoSec Medical; Pfizer; Incyte; AstraZeneca; Amarin Corporation; Castle Biosciences; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Sanofi; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Amgen; GlaxoSmithKline","keywords":"Ipilimumab; Pembrolizumab; Adjuvant; Melanoma; Blockade; Immunotherapy; Adjuvant therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001603556,0.0004489853,0.0008801453,0.0001515836,0.0001701551,0.0003722028,0.0003327505,0.0004735915,0.001255431],"category_scores_gemma":[0.001410172,0.0002508261,0.001026166,0.0001650916,0.0004340821,0.0002555314,0.0001557358,0.00110779,0.0001809244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004641024,"about_ca_system_score_gemma":0.0008312094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005767739,"about_ca_topic_score_gemma":0.001776107,"domain_scores_codex":[0.9995502,0.0003057622,0.00002571638,0.00004424652,0.00003234296,0.0000417532],"domain_scores_gemma":[0.9993685,0.0002294225,0.0001924875,0.00003113836,0.00002364131,0.0001548439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8685913,0.007506588,0.01851988,0.001159965,0.002250215,0.0001704919,0.00008709825,0.00150998,0.01513043,0.000121037,0.0006687944,0.08428428],"study_design_scores_gemma":[0.6710562,0.2702247,0.04705335,0.0001899489,0.002687589,0.0003331926,0.00006908597,0.002244838,0.004137,0.0003874941,0.001594346,0.00002231898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952128,0.003789342,0.0001889471,0.0002004161,0.00007691324,0.0002006072,0.00007668421,0.000009847015,0.0002445685],"genre_scores_gemma":[0.9970338,0.001431552,0.0005271803,0.0002181553,0.00009839679,0.0002524626,0.0001158609,0.00000231986,0.0003202439],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001603556,"threshold_uncertainty_score":0.008480549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02601356629115556,"score_gpt":0.3044026289868365,"score_spread":0.2783890626956809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}